Application of lectin group recognized carbohydrate chain in distinguishing mucinous cystic neoplasm from serous cystic neoplasm

Abstract

The invention discloses application of lectin group recognized carbohydrate chains in distinguishing mucinous cystic neoplasm from serous cystic neoplasm. The lectin group recognized carbohydrate chains disclosed by the invention are glycosylated protein carbohydrate chains recognized by lectin groups consisting of WGA (trticum vulgaris agglutinin), BPL (bauhinia purpurea lectin), STL (solanum tuberosum (potato) lectin), DBA (dolchos biflorus agglutinin), PTL-I (psophocarpus tetragonolobus lectin I) and MAL-I (maackia amurensis lectin I). The carbohydrate chains are different in capsula pancreatic fluid of patients suffering from mucinous cystic neoplasm and serous cystic neoplasm, the contents of the carbohydrate chains recognized by STL, WGA, BPL and DBA in the capsula pancreatic fluid of patients suffering from MCN (mucinous cystic neoplasm) are remarkably higher than those in the capsula pancreatic fluid of patients suffering from SCN (serous cystic neoplasm), the contents of the carbohydrate chains recognized by PTL-I and MAL-I in the capsula pancreatic fluid of the patients suffering from MCN are remarkably lower than those in the capsula pancreatic fluid of the patients suffering from SCN, the sensitivity of the combination of WGA and BPL in distinguishing the patients suffering from SCN from the patients suffering from MCN is 0.714, and the specificity is 1. The results show that the lectin group can be used for distinguishing the patients from SCN from the patients suffering from MCN.

Description

Technical field [0001] The invention relates to the application of sugar chains recognized by a lectin group in the field of biotechnology to distinguish pancreatic mucinous cystic tumors from pancreatic serous cystic tumors. Background technique [0002] With the advancement and wide application of imaging technology, the detection rate of pancreatic cyst lesion (PCL) has been increasing year by year. Recent studies in the United States have calculated that the total prevalence of PCL is 2.5%. Pancreatic cystic lesions are heterogeneous lesions composed of a group of different pathological types with common clinical symptoms, mainly including simple pancreatic pseudocysts (PPs) And pancreatic cystic neoplasms (PCNs). PCNs are insidious and have no obvious signs in the early stage. They are mainly characterized by glandular duct or acinar epithelial hyperplasia and secretion retention to form cysts, which account for about 1% to 5% of all primary pancreatic tumors. The 2010 WHO...

AI Technical Summary

Problems solved by technology

Different pathological types have different treatment methods, but it is difficult to distinguish between benign and malignant tumors based on clinical symptoms and imaging manifestations. Cystic lesions are usually found by CT, but the sensitivity of CT for diagnosing malignant tumors is less than 70%, while the specificity is low. Between 87%-98%, the T2WI phase of MRI can provide better soft tissue contrast, so it is more commonly used in the differential diagnosis of benign and malignant cysts, but its accuracy still stays in the lower range of 20%-80%

The accuracy of distinguishing benign and malignant cystic lesions from imaging alone is still low. At the same time, commonly used serological tumor markers: CEA; CA19-9; CA72-4 and CA153, etc., are specific and sensitive in distinguishing precancerous lesions lower

Images